Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
41.83
-1.38 (-3.19%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Merus Revenue
In the year 2024, Merus had annual revenue of $36.13M, down -17.78%. Merus had revenue of $9.14M in the quarter ending December 31, 2024, with 2.25% growth.
Revenue (ttm)
$36.13M
Revenue Growth
-17.78%
P/S Ratio
74.35
Revenue / Employee
$112,564
Employees
321
Market Cap
2.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36.13M | -7.81M | -17.78% |
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MRUS News
- 19 hours ago - Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - GlobeNewsWire
- 17 days ago - Merus: Riding The Bispecific Wave In Oncology - Seeking Alpha
- 22 days ago - Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewsWire
- 2 months ago - Merus to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma - GlobeNewsWire
- 2 months ago - Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - GlobeNewsWire
- 2 months ago - New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewsWire